1. MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). (12th June 2019) Authors: Hill, B.T.; Switchenko, J.M.; Martin, P.; Churnetski, M.C.; Sawalha, Y.; Goyal, S.; Shanmugasundaram, K.; Calzada, O.; Kolla, B.; Bachanova, V.; Gerson, J.N.; Barta, S.K.; Maldonado, E.; Gordon, M.; Danilov, A.; Grover, N.S.; Mathews, S.; Burkart, M.; Karmali, R.; Ghosh, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES. (June 2017) Authors: Hamlin, P.A.; Farber, C.M.; Fenske, T.S.; Khatcheressian, J.L.; Miller, C.B.; Munoz, J.; Patel, M.R.; Schreeder, M.T.; Smith, S.M.; Stevens, D.A.; Pandey, A.; Birrell, M.R.; Leeds, J.M.; Wang, Y.L.; Coffey, G.P.; Curnutte, J.T. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗